Podcast

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

Author(s):

OncLive Staff

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.

OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Geoffrey R. Oxnard, MD, vice president, global medical lead, liquid franchise, at Foundation Medicine, to discuss the current state of treatment in lung cancer and the potential reach of liquid biopsy in the field.

In our exclusive interview, Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.
Related Content
Jonathan D. Spicer, MD, PhD, FRCS, of McGill University Health Centre
November 14th 2024

Perioperative Durvalumab Plus Chemotherapy Represents the Future of Personalized NSCLC Care

Premal Thaker, MD, MS, David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, director, Gynecologic Oncology Clinical Research, interim chief, Division of Gynecologic Oncology, School of Medicine, Washington University in St. Louis, Siteman Cancer Center
November 11th 2024

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
November 7th 2024

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

Vinayak Venkataraman, MD
November 11th 2024

Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3